Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01216176
What this trial is testing

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Who this might be right for
Breast Cancer
Joyce Marie Slingerland, MD 71
Not applicableActive Not RecruitingNCT07493291
What this trial is testing

Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Breast Cancer Patients

Who this might be right for
Brest CancerCDK4/6 Inhibitor
Al-Mustansiriyah University 100
Testing effectiveness (Phase 2)Looking for participantsNCT07164976
What this trial is testing

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Nagoya City University 86
Large-scale testing (Phase 3)Study completedNCT03096847
What this trial is testing

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals 502
Testing effectiveness (Phase 2)Study completedNCT00128843
What this trial is testing

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 103
Large-scale testing (Phase 3)Study completedNCT00065325
What this trial is testing

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
AstraZeneca 694
Post-approval studies (Phase 4)Ended earlyNCT03220178
What this trial is testing

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

Who this might be right for
Breast Neoplasm
Palleos Healthcare GmbH 532
Testing effectiveness (Phase 2)Active Not RecruitingNCT02747004
What this trial is testing

Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 234
Early research (Phase 1)Looking for participantsNCT07020117
What this trial is testing

[225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Who this might be right for
Urothelial Carcinoma BladderTriple Negative Breast Cancer (TNBC)Hormone Receptor Positive Breast Adenocarcinoma+4 more
Aktis Oncology, Inc. 150
Testing effectiveness (Phase 2)Looking for participantsNCT07612891
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor

Who this might be right for
Breast Cancer (Locally Advanced or Metastatic)Advanced Solid CancersMetastatic (Stage IV) Breast Cancer+2 more
Shenzhen Ionova Life Sciences Co., Ltd.
Large-scale testing (Phase 3)Ended earlyNCT05207709
What this trial is testing

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 61
Testing effectiveness (Phase 2)Study completedNCT00146601
What this trial is testing

Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 35
Testing effectiveness (Phase 2)Study completedNCT03691493
What this trial is testing

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu Negative+4 more
Emory University 36
Not applicableStudy completedNCT04460911
What this trial is testing

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

Who this might be right for
Breast Cancer
Pfizer 317
Large-scale testing (Phase 3)Study completedNCT03176238
What this trial is testing

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Post Menopausal Breast Cancer
Novartis Pharmaceuticals 235
Testing effectiveness (Phase 2)Study completedNCT00728949
What this trial is testing

Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 93
Large-scale testing (Phase 3)Study completedNCT01602380
What this trial is testing

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

Who this might be right for
Hormone Receptor Positive Breast Cancer
AstraZeneca 462
Not applicableStudy completedNCT06086340
What this trial is testing

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Who this might be right for
Breast Cancer
Pfizer 779
Testing effectiveness (Phase 2)UnknownNCT04034589
What this trial is testing

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 46
Large-scale testing (Phase 3)Ended earlyNCT01633060
What this trial is testing

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 432
Next Page
201